首页 | 本学科首页   官方微博 | 高级检索  
检索        

DNA修复基因ERCC1在原发性肝细胞癌组织中的表达及临床意义
引用本文:谢伟敏,房亮,梁安民,陆永奎,周文献,王洪学,胡晓桦,廖小莉,李瑗,张春燕,周钢桥,张红星,黎乐群.DNA修复基因ERCC1在原发性肝细胞癌组织中的表达及临床意义[J].中国肿瘤临床,2012,39(14):957-961.
作者姓名:谢伟敏  房亮  梁安民  陆永奎  周文献  王洪学  胡晓桦  廖小莉  李瑗  张春燕  周钢桥  张红星  黎乐群
作者单位:①.广西医科大学附属肿瘤医院化疗科(南宁市530021)
基金项目:国家科技重大专项项目(编号:2008ZX10002-016);国家自然科学基金(编号:30560167,81060173和30960021);广西科学基金项目(编号:桂科青0542064);广西医疗卫生重点科研项目(编号:重200610);广西研究生教育创新计划项目[编号:桂学位(2010)44号]资助~~
摘    要:   目的  探讨切除修复交叉互补基因1(ERCC1)在原发性肝细胞癌(Hepatocellular carcinoma, HCC)组织中的表达情况及临床意义。   方法  应用免疫组织化学方法检测226例HCC癌组织、65例HCC癌旁组织和17例非癌肝组织中ERCC1的表达情况, 并分析其与HCC临床病理因素和预后的关系。   结果  肝癌组织中ERCC1阳性率为44.2%(100/226), 显著高于癌旁组织及非癌正常肝组织中的阳性率(分别为16.9%和5.9%, P < 0.05)。有门静脉癌栓组的ERCC1阳性率为66.7%, 无癌栓组为42.3%, 差异具有统计学意义(P < 0.05);但ERCC1阳性表达与性别等其他临床病理特征均无关(P均 > 0.05)。接受根治术的184例患者中, ERCC1阳性率随着中位复发转移时间(TTR/M)的延长而显著降低(χ2=9.630, P=0.047);ERCCI阳性组TTR/M为10.3个月, 而阴性表达组为20.3个月, 差异具有统计学意义(P < 0.05)。多因素生存分析显示, 术前谷草转氨酶 > 2.5倍正常值、病灶最大径 > 5 cm和ERCCl阳性表达是HCC患者术后复发转移风险增加的独立危险因素。   结论  肝癌组织中ERCCl阳性率显著高于癌旁肝组织及非癌肝组织, 其阳性表达与门静脉癌栓形成及术后复发、转移风险增高显著相关。 

关 键 词:肝细胞癌    ERCC1    免疫组织化学    复发    转移
收稿时间:2012-04-05

Clinical Significance of ERCCl Expression in Primary Hepatocellular Carcinoma
Weimin XIE,Liang FANG,Anmin LIANG,Yongkui LU,Wenxian ZHOU,Hongxue WANG,Xiaohua HU,Xiaoli LIAO,Yuan LI, Chunyan ZHANG,Gangqiao ZHOU,Hongxing ZHANG,Lequn LI.Clinical Significance of ERCCl Expression in Primary Hepatocellular Carcinoma[J].Chinese Journal of Clinical Oncology,2012,39(14):957-961.
Authors:Weimin XIE  Liang FANG  Anmin LIANG  Yongkui LU  Wenxian ZHOU  Hongxue WANG  Xiaohua HU  Xiaoli LIAO  Yuan LI  Chunyan ZHANG  Gangqiao ZHOU  Hongxing ZHANG  Lequn LI
Institution:①.Department of Chemotherapy, The Affiliated Hospital of Guangxi Medical University, Nanning 530021, China②.Department of Oncology, The Central Hospital of Hengyang, Hengyang 421001, China③.Department of Hepatobiliary Surgery, The Affiliated Hospital of Guangxi Medical University, Nanning 530021, China④.Oncology Experiment Center, The Affiliated Hospital of Guangxi Medical University, Nanning 530021, China⑤.Beijing Proteome Research Center (BPRC), Beijing 102206, China
Abstract:   Objective  This study aims to investigate the expression of excision repair cross complementing 1(ERCCl) of hepatocellular carcinoma(HCC) and its clinical significance.   Methods  The ERCC1 expression status of 226 patients with HCC, 65 with paraneoplastic tissue, and 17 with normal liver tissues was detected using immunohistochemistry.The correlation between ERCC 1 expression and major clinico-pathological characteristics and prognosis factors of HCC was analyzed.   Results  The positive expression rate of ERCC1 in HCC was 44.2%(100 / 226), which was significantly higher compared with the paraneoplastic and non-cancer liver tissues(16.9% and 5.9%, respectively, all P < 0.05).The positive rate of ERCC1 in HCC cases with portal vein invasion was significantly higher compared with those without portal vein invasion(66.7%vs.42.3%, P < 0.05).Meanwhile, the expression of ERCC1 was not significantly associated with age and other clinical characteristics(P > 0.05, respectively).In the HCC group treated with radical resection(184 patients), the positive rate of ERCC 1 noticeably decreased when the median time to recurrence or metastasis(TTR /M) became longer.The group with positive expression of ERCC1 exhibited a shorter TTR/M compared with the group with negative expression(10.3 m vs.20.3 m, P < 0.05).The Cox regression model analysis showed that the preoperative serum levels of aspartate amionotransferase≥2.5 N, tumor size > 5 cm, and the positive expression of ERCC1 were the independent risk factors of recurrence or metastasis of HCC.   Conclusion  ERCC1 expression was obviously higher in HCC than in the paraneoplastic and normal liver tissues, respectively.The overexpression of ERCC1 was significantly correlated with the portal vein invasion and the risk of recurrence or metastasis of HCC after radical resection. 
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号